Mucosal vaccine delivery: Current state and a pediatric perspective

Journal of Controlled Release

Volumn 240, Issue , 2016, Pages 394-413

  Shakya, Akhilesh Kumar ^a   Chowdhury, Mohammed Y E ^a   Tao, Wenqian ^a   Gill, Harvinder Singh ^a  

^a Texas Tech University   (United States)

Author keywords

Intranasal vaccination; Mucosal vaccination; Nasal vaccination; Oral cavity vaccination; Oral vaccination; Pollen grains; Skin vaccination

Indexed keywords

ENZYMES; PATHOGENS; PEDIATRICS;

INTRANASAL; MUCOSAL VACCINATION; NASAL VACCINATION; ORAL CAVITY; ORAL VACCINATIONS; POLLEN GRAINS; SKIN VACCINATIONS;

VACCINES;

CHOLERA VACCINE; INFLUENZA VACCINE; LIPOSOME; ORAL POLIOMYELITIS VACCINE; POLIOMYELITIS VACCINE; POLYMER; ROTAVIRUS VACCINE; TYPHOID VACCINE; VACCINE; DRUG CARRIER; IMMUNOLOGICAL ADJUVANT;

ARTICLE; BRONCHUS ASSOCIATED LYMPHOID TISSUE; DRUG DELIVERY SYSTEM; HUMAN; INTESTINE LYMPHATIC TISSUE; LYMPH NODE; LYMPHOID TISSUE; MICRONEEDLE; MOUTH CAVITY; MUCOSA ASSOCIATED LYMPHOID TISSUE; MUCOSAL IMMUNITY; NASOPHARYNX ASSOCIATED LYMPHOID TISSUE; NONHUMAN; PEYER PATCH; PRIORITY JOURNAL; VACCINATION; VIRUS LIKE AGENT; CHEMISTRY; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PEDIATRICS; PROCEDURES; TRENDS;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ADMINISTRATION, ORAL; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNITY, MUCOSAL; LIPOSOMES; LYMPHOID TISSUE; PEDIATRICS; VACCINES;

EID: 84964371820     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2016.02.014     Document Type: Article

References (259)

1. [1] Liu, L., Oza, S., Hogan, D., Perin, J., Rudan, I., Lawn, J.E., Cousens, S., Mathers, C., Black, R.E., Global, regional, and national causes of child mortality in 2000–13, with projections to inform post-2015 priorities: an updated systematic analysis. Lancet 385 (2015), 430–440.
2. [2] Holmgren, J., Czerkinsky, C., Mucosal immunity and vaccines. Nat. Med. 11 (2005), S45–S53.
3. [3] Lycke, N., Recent progress in mucosal vaccine development: potential and limitations. Nat. Rev. Immunol. 12 (2012), 592–605.
4. [4] Russell, M.W., Mestecky, J., Chapter 55 — Mucosal Vaccines: An Overview. Mestecky, J., Strober, W., Russell, M.W., Kelsall, B.L., Cheroutre, H., Lambrecht, B.N., (eds.) Mucosal Immunology (Fourth Edition), 2015, Academic Press, Boston, 1039–1046.
5. [5] Hauri, A.M., Armstrong, G.L., Hutin, Y.J.F., The global burden of disease attributable to contaminated injections given in health care settings. Int. J. STD AIDS 15 (2004), 7–16.
6. [6] World Health Organization, Cholera vaccines: WHO position paper. Wkly Epidemiol. Rec. 85 (2010), 117–128.
7. [7] World Health Organization, Vaccines against influenza WHO position paper — November 2012. Wkly Epidemiol. Rec. 87 (2012), 461–476.
8. [8] World Health Organization, Polio vaccines: WHO position paper, January 2014. Wkly Epidemiol. Rec. 89 (2014), 73–92.
9. [9] World Health Organization, Rotavirus vaccines WHO position paper — January 2013. Wkly Epidemiol. Rec. 88 (2013), 49–64.
10. [10] World Health Organization, Typhoid vaccines: WHO position paper. Wkly Epidemiol. Rec. 83 (2008), 49–60.
11. [11] Neutra, M.R., Kozlowski, P.A., Mucosal vaccines: the promise and the challenge. Nat. Rev. Immunol. 6 (2006), 148–158.
12. [12] Russell, M., Mestecky, J., Strober, W., Lambrecht, B.N., Kelsall, B.L., Cheroutre, H., Chapter 1 — Overview: the Mucosal Immune System. Mestecky, J., Strober, W., Russell, M.W., Kelsall, B.L., Cheroutre, H., Lambrecht, B.N., (eds.) Mucosal Immunology, fourth ed., 2015, Academic Press, Boston, 3–8.
13. [13] Strugnell, R.A., Wijburg, O.L., The role of secretory antibodies in infection immunity. Nat. Rev. Microbiol. 8 (2010), 656–667.
14. [14] Rojas, R., Apodaca, G., Immunoglobulin transport across polarized epithelial cells. Nat. Rev. Mol. Cell Biol. 3 (2002), 944–955.
15. [15] Phalipon, A., Cardona, A., Kraehenbuhl, J.P., Edelman, L., Sansonetti, P.J., Corthesy, B., Secretory component: a new role in secretory IgA-mediated immune exclusion in vivo. Immunity 17 (2002), 107–115.
16. [16] Kaetzel, C.S., Robinson, J.K., Chintalacharuvu, K.R., Vaerman, J.P., Lamm, M.E., The polymeric immunoglobulin receptor (secretory component) mediates transport of immune complexes across epithelial cells: a local defense function for IgA. Proc. Natl. Acad. Sci. U. S. A. 88 (1991), 8796–8800.
17. [17] Hornquist, C.E., Ekman, L., Grdic, K.D., Schon, K., Lycke, N.Y., Paradoxical IgA immunity in CD4-deficient mice. lack of cholera toxin-specific protective immunity despite normal gut mucosal IgA differentiation. J. Immunol. 155 (1995), 2877–2887.
18. [18] Goodrich, M.E., McGee, D.W., Regulation of mucosal B cell immunoglobulin secretion by intestinal epithelial cell-derived cytokines. Cytokine 10 (1998), 948–955.
19. [19] Asano, T., Kaneko, H., Terada, T., Kasahara, Y., Fukao, T., Kasahara, K., Kondo, N., Molecular analysis of B-cell differentiation in selective or partial IgA deficiency. Clin. Exp. Immunol. 136 (2004), 284–290.
20. [20] Kunkel, E.J., Butcher, E.C., Plasma-cell homing. Nat. Rev. Immunol. 3 (2003), 822–829.
21. [21] Simmons, C.P., Hussell, T., Sparer, T., Walzl, G., Openshaw, P., Dougan, G., Mucosal delivery of a respiratory syncytial virus CTL peptide with enterotoxin-based adjuvants elicits protective, immunopathogenic, and immunoregulatory antiviral CD8 + T cell responses. J. Immunol. 166 (2001), 1106–1113.
22. [22] Cesta, M.F., Normal structure, function, and histology of mucosa-associated lymphoid tissue. Toxicol. Pathol. 34 (2006), 599–608.
23. [23] Azzali, G., Structure, lymphatic vascularization and lymphocyte migration in mucosa-associated lymphoid tissue. Immunol. Rev. 195 (2003), 178–189.
24. [24] Flach, M., Diefenbach, A., Chapter 3 — Development of Gut-Associated Lymphoid Tissues. Mestecky, J., Strober, W., Russell, M.W., Kelsall, B.L., Cheroutre, H., Lambrecht, B.N., (eds.) Mucosal Immunology (Fourth Edition), 2015, Academic Press, Boston, 31–42.
25. [25] Kunisawa, J., Kurashima, Y., Kiyono, H., Gut-associated lymphoid tissues for the development of oral vaccines. Adv. Drug Deliv. Rev. 64 (2012), 523–530.
26. [26] Dobbins, W.O. III, Human intestinal intraepithelial lymphocytes. Gut 27 (1986), 972–985.
27. [27] Cheroutre, H., Lambolez, F., Mucida, D., The light and dark sides of intestinal intraepithelial lymphocytes. Nat. Rev. Immunol. 11 (2011), 445–456.
28. [28] Perry, M., Whyte, A., Immunology of the tonsils. Immunol. Today 19 (1998), 414–421.
29. [29] Bienenstock, J., McDermott, M.R., Bronchus- and nasal-associated lymphoid tissues. Immunol. Rev. 206 (2005), 22–31.
30. [30] Howie, A.J., Scanning and transmission electron microscopy on the epithelium of human palatine tonsils. J. Pathol. 130 (1980), 91–98.
31. [31] Chadwick, S., Kriegel, C., Amiji, M., Delivery strategies to enhance mucosal vaccination. Expert. Opin. Biol. Ther. 9 (2009), 427–440.
32. [32] Fujihashi, K., Dohi, T., Rennert, P.D., Yamamoto, M., Koga, T., Kiyono, H., McGhee, J.R., Peyer's patches are required for oral tolerance to proteins. Proc. Natl. Acad. Sci. U. S. A. 98 (2001), 3310–3315.
33. [33] Morag, A., Morag, B., Bernstein, J.M., Beutner, K., Ogra, P.L., In vitro correlates of cell-mediated immunity in human tonsils after natural or induced Rubella virus infection. J. Infect. Dis. 131 (1975), 409–416.
34. [34] Sminia, T., van der Brugge-Gamelkoorn, G.J., Jeurissen, S.H., Structure and function of bronchus-associated lymphoid tissue (BALT). Crit. Rev. Immunol. 9 (1989), 119–150.
35. [35] Halle, S., Dujardin, H.C., Bakocevic, N., Fleige, H., Danzer, H., Willenzon, S., Suezer, Y., Hammerling, G., Garbi, N., Sutter, G., Worbs, T., Forster, R., Induced bronchus-associated lymphoid tissue serves as a general priming site for T cells and is maintained by dendritic cells. J. Exp. Med. 206 (2009), 2593–2601.
36. [36] Tango, M., Suzuki, E., Gejyo, F., Ushiki, T., The presence of specialized epithelial cells on the bronchus-associated lymphoid tissue (BALT) in the mouse. Arch. Histol. Cytol. 63 (2000), 81–89.
37. [37] Gregson, R.L., Edmondson, N.A., Plesch, B., Preferential uptake of soluble antigen by respiratory tract epithelium overlying bronchus-associated lymphoid tissue in the rat. Adv. Exp. Med. Biol. 149 (1982), 499–505.
38. [38] Pabst, R., Gehrke, I., Is the bronchus-associated lymphoid tissue (BALT) an integral structure of the lung in normal mammals, including humans?. Am. J. Respir. Cell Mol. Biol. 3 (1990), 131–135.
39. [39] Pabst, R., Tschernig, T., Bronchus-associated lymphoid tissue. Am. J. Respir. Cell Mol. Biol. 43 (2010), 137–141.
40. [40] Ersch, J., Tschernig, T., Stallmach, T., Frequency and potential cause of bronchus-associated lymphoid tissue in fetal lungs. Pediatr. Allergy Immunol. 16 (2005), 295–298.
41. [41] Kawamata, N., Xu, B., Nishijima, H., Aoyama, K., Kusumoto, M., Takeuchi, T., Tei, C., Michie, S.A., Matsuyama, T., Expression of endothelia and lymphocyte adhesion molecules in bronchus-associated lymphoid tissue (BALT) in adult human lung. Respir. Res., 10, 2009, 97.
42. [42] McGuckin, M.A., Thornton, D.J., Whitsett, J.A., Chapter 14 — Mucins and Mucus. Mestecky, J., Strober, W., Russell, M.W., Kelsall, B.L., Cheroutre, H., Lambrecht, B.N., (eds.) Mucosal Immunology (Fourth Edition), 2015, Academic Press, Boston, 231–250.
43. [43] Groschwitz, K.R., Hogan, S.P., Intestinal barrier function: molecular regulation and disease pathogenesis. J. Allergy Clin. Immunol. 124 (2009), 3–20 quiz 21-22.
44. [44] Clark, M.A., Jepson, M.A., Hirst, B.H., Exploiting M cells for drug and vaccine delivery. Adv. Drug Deliv. Rev. 50 (2001), 81–106.
45. [45] Bland, P.W., Warren, L.G., Antigen presentation by epithelial cells of the rat small intestine. II. Selective induction of suppressor T cells. Immunology 58 (1986), 9–14.
46. [46] Rescigno, M., Urbano, M., Valzasina, B., Francolini, M., Rotta, G., Bonasio, R., Granucci, F., Kraehenbuhl, J.P., Ricciardi-Castagnoli, P., Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. Nat. Immunol. 2 (2001), 361–367.
47. [47] Niess, J.H., Brand, S., Gu, X., Landsman, L., Jung, S., McCormick, B.A., Vyas, J.M., Boes, M., Ploegh, H.L., Fox, J.G., Littman, D.R., Reinecker, H.C., CX3CR1-mediated dendritic cell access to the intestinal lumen and bacterial clearance. Science 307 (2005), 254–258.
48. [48] Campbell, D.J., Debes, G.F., Johnston, B., Wilson, E., Butcher, E.C., Targeting T cell responses by selective chemokine receptor expression. Semin. Immunol. 15 (2003), 277–286.
49. [49] Quiding, M., Nordstrom, I., Kilander, A., Andersson, G., Hanson, L.A., Holmgren, J., Czerkinsky, C., Intestinal immune responses in humans. Oral cholera vaccination induces strong intestinal antibody responses and interferon-gamma production and evokes local immunological memory. J. Clin. Invest. 88 (1991), 143–148.
50. [50] Kozlowski, P.A., Cu-Uvin, S., Neutra, M.R., Flanigan, T.P., Comparison of the oral, rectal, and vaginal immunization routes for induction of antibodies in rectal and genital tract secretions of women. Infect. Immun. 65 (1997), 1387–1394.
51. [51] Johansson, E.L., Wassen, L., Holmgren, J., Jertborn, M., Rudin, A., Nasal and vaginal vaccinations have differential effects on antibody responses in vaginal and cervical secretions in humans. Infect. Immun. 69 (2001), 7481–7486.
52. [52] Russell-Jones, G.J., Oral vaccine delivery. J. Control. Release 65 (2000), 49–54.
53. [53] Kim, S.H., Jang, Y.S., Antigen targeting to M cells for enhancing the efficacy of mucosal vaccines. Exp. Mol. Med., 46, 2014, e85.
54. [54] Singh, B., Maharjan, S., Jiang, T., Kang, S.K., Choi, Y.J., Cho, C.S., Combinatorial approach of antigen delivery using M cell-homing peptide and mucoadhesive vehicle to enhance the efficacy of oral vaccine. Mol. Pharm., 2015.
55. [55] Rieux, A. des, Fievez, V., Garinot, M., Schneider, Y.J., Preat, V., Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J. Control. Release 116 (2006), 1–27.
56. [56] Liau, J.J., Hook, S., Prestidge, C.A., Barnes, T.J., A lipid based multi-compartmental system: liposomes-in-double emulsion for oral vaccine delivery. Eur. J. Pharm. Biopharm., 2015.
57. [57] Ugwoke, M.I., Verbeke, N., Kinget, R., The biopharmaceutical aspects of nasal mucoadhesive drug delivery. J. Pharm. Pharmacol. 53 (2001), 3–21.
58. [58] Brandtzaeg, P., Immune Functions of Nasopharyngeal Lymphoid Tissue. 2011.
59. [59] Mall, M.A., Role of cilia, mucus, and airway surface liquid in mucociliary dysfunction: lessons from mouse models. J. Aerosol Med. Pulm. Drug Deliv. 21 (2008), 13–24.
60. [60] Pires, A., Fortuna, A., Alves, G., Falcão, A., Intranasal Drug Delivery: how, why and What for?. 2009.
61. [61] Patel, V.F., Liu, F., Brown, M.B., Advances in oral transmucosal drug delivery. J. Control. Release 153 (2011), 106–116.
62. [62] Hearnden, V., Sankar, V., Hull, K., Juras, D.V., Greenberg, M., Kerr, A.R., Lockhart, P.B., Patton, L.L., Porter, S., Thornhill, M.H., New developments and opportunities in oral mucosal drug delivery for local and systemic disease. Adv. Drug Deliv. Rev. 64 (2012), 16–28.
63. [63] Pather, S.I., Rathbone, M.J., Senel, S., Current status and the future of buccal drug delivery systems. Expert Opin. Drug Deliv. 5 (2008), 531–542.
64. [64] Barrett, A.W., Cruchley, A.T., Williams, D.M., Oral mucosal Langerhans’ cells. Crit. Rev. Oral Biol. Med. 7 (1996), 36–58.
65. [65] Hasseus, B., Jontell, M., Bergenholtz, G., Dahlgren, U.I., Langerhans cells from human oral epithelium are more effective at stimulating allogeneic T cells in vitro than Langerhans cells from skin. Clin. Exp. Immunol. 136 (2004), 483–489.
66. [66] Desvignes, C., Esteves, F., Etchart, N., Bella, C., Czerkinsky, C., Kaiserlian, D., The murine buccal mucosa is an inductive site for priming class I-restricted CD8 + effector T cells in vivo. Clin. Exp. Immunol. 113 (1998), 386–393.
67. [67] Lu, F.X., Jacobson, R.S., Oral mucosal immunity and HIV/SIV infection. J. Dent. Res. 86 (2007), 216–226.
68. [68] Kraan, H., Vrieling, H., Czerkinsky, C., Jiskoot, W., Kersten, G., Amorij, J.P., Buccal and sublingual vaccine delivery. J. Control. Release 190 (2014), 580–592.
69. [69] Hervouet, C., Luci, C., Bekri, S., Juhel, T., Bihl, F., Braud, V.M., Czerkinsky, C., Anjuere, F., Antigen-bearing dendritic cells from the sublingual mucosa recirculate to distant systemic lymphoid organs to prime mucosal CD8 T cells. Mucosal Immunol. 7 (2014), 280–291.
70. [70] Arora, A., Prausnitz, M.R., Mitragotri, S., Micro-scale devices for transdermal drug delivery. Int. J. Pharm. 364 (2008), 227–236.
71. [71] Karande, P., Arora, A., Pham, T.K., Stevens, D., Wojicki, A., Mitragotri, S., Transcutaneous immunization using common chemicals. J. Control. Release 138 (2009), 134–140.
72. [72] Nicolas, J.-F., Guy, B., Intradermal, epidermal and transcutaneous vaccination: from immunology to clinical practice. Expert Rev. Vaccines 7 (2008), 1201–1214.
73. [73] Belyakov, I.M., Hammond, S.A., Ahlers, J.D., Glenn, G.M., Berzofsky, J.A., Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells. J. Clin. Invest. 113 (2004), 998–1007.
74. [74] Chang, S.Y., Cha, H.R., Igarashi, O., Rennert, P.D., Kissenpfennig, A., Malissen, B., Nanno, M., Kiyono, H., Kweon, M.N., Cutting edge: langerin + dendritic cells in the mesenteric lymph node set the stage for skin and gut immune system cross-talk. J. Immunol. 180 (2008), 4361–4365.
75. [75] Jabbal-Gill, I., Nasal vaccine innovation. J. Drug Target. 18 (2010), 771–786.
76. [76] Sridhar, S., Brokstad, K.A., Cox, R.J., Influenza vaccination strategies: comparing inactivated and live attenuated influenza vaccines. Vaccine 3 (2015), 373–389.
77. [77] Azizi, A., Kumar, A., Diaz-Mitoma, F., Mestecky, J., Enhancing oral vaccine potency by targeting intestinal M cells. PLoS Pathog., 6, 2010, e1001147.
78. [78] Tucker, S.N., Tingley, D.W., Scallan, C.D., Oral adenoviral-based vaccines: historical perspective and future opportunity. Expert Rev. Vaccines 7 (2008), 25–31.
79. [79] Kotton, C.N., Lankowski, A.J., Scott, N., Sisul, D., Chen, L.M., Raschke, K., Borders, G., Boaz, M., Spentzou, A., Galan, J.E., Hohmann, E.L., Safety and immunogenicity of attenuated Salmonella enterica serovar Typhimurium delivering an HIV-1 Gag antigen via the Salmonella Type III secretion system. Vaccine 24 (2006), 6216–6224.
80. [80] Chowdhury, M.Y., Seo, S.K., Moon, H.J., Talactac, M.R., Kim, J.H., Park, M.E., Son, H.Y., Lee, J.S., Kim, C.J., Heterosubtypic protective immunity against widely divergent influenza subtypes induced by fusion protein 4sM2 in BALB/c mice. Virol. J., 11, 2014, 21.
81. [81] He, X.-S., Holmes, T.H., Zhang, C., Mahmood, K., Kemble, G.W., Lewis, D.B., Dekker, C.L., Greenberg, H.B., Arvin, A.M., Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines. J. Virol. 80 (2006), 11756–11766.
82. [82] Turner, P.J., Southern, J., Andrews, N.J., Miller, E., Erlewyn-Lajeunesse, M., Investigators, S.S., Safety of live attenuated influenza vaccine in atopic children with egg allergy. J. Allergy Clin. Immunol., 2015.
83. [83] Shata, M.T., Hone, D.M., Vaccination with a Shigella DNA vaccine vector induces antigen-specific CD8(+) T cells and antiviral protective immunity. J. Virol. 75 (2001), 9665–9670.
84. [84] Chowdhury, M.Y., Li, R., Kim, J.H., Park, M.E., Kim, T.H., Pathinayake, P., Weeratunga, P., Song, M.K., Son, H.Y., Hong, S.P., Sung, M.H., Lee, J.S., Kim, C.J., Mucosal vaccination with recombinant Lactobacillus casei-displayed CTA1-conjugated consensus matrix protein-2 (sM2) induces broad protection against divergent influenza subtypes in BALB/c mice. PLoS One, 9, 2014, e94051.
85. [85] Li, R., Chowdhury, M.Y., Kim, J.H., Kim, T.H., Pathinayake, P., Koo, W.S., Park, M.E., Yoon, J.E., Roh, J.B., Hong, S.P., Sung, M.H., Lee, J.S., Kim, C.J., Mucosally administered Lactobacillus surface-displayed influenza antigens (sM2 and HA2) with cholera toxin subunit A1 (CTA1) induce broadly protective immune responses against divergent influenza subtypes. Vet. Microbiol. 179 (2015), 250–263.
86. [86] Hopkins, S., Kraehenbuhl, J.P., Schodel, F., Potts, A., Peterson, D., de Grandi, P., Nardelli-Haefliger, D., A recombinant Salmonella typhimurium vaccine induces local immunity by four different routes of immunization. Infect. Immun. 63 (1995), 3279–3286.
87. [87] Friedman, R.S., Frankel, F.R., Xu, Z., Lieberman, J., Induction of human immunodeficiency virus (HIV)-specific CD8 T-cell responses by Listeria monocytogenes and a hyperattenuated Listeria strain engineered to express HIV antigens. J. Virol. 74 (2000), 9987–9993.
88. [88] Thippeshappa, R., Tian, B., Cleveland, B., Guo, W., Polacino, P., Hu, S.-L., Oral immunization with recombinant vaccinia virus prime and intramuscular protein boost provides protection against intra-rectal SHIV challenge in macaques. Clin. Vaccine Immunol., 2015.
89. [89] Çuburu, N., Kweon, M.-N., Song, J.-H., Hervouet, C., Luci, C., Sun, J.-B., Hofman, P., Holmgren, J., Anjuère, F., Czerkinsky, C., Sublingual immunization induces broad-based systemic and mucosal immune responses in mice. Vaccine 25 (2007), 8598–8610.
90. [90] van der Lubben, I.M., Verhoef, J.C., Borchard, G., Junginger, H.E., Chitosan for mucosal vaccination. Adv. Drug Deliv. Rev. 52 (2001), 139–144.
91. [91] Irvine, D.J., Hanson, M.C., Rakhra, K., Tokatlian, T., Synthetic nanoparticles for vaccines and immunotherapy. Chem. Rev. 115 (2015), 11109–11146.
92. [92] Brayden, D.J., Baird, A.W., Microparticle vaccine approaches to stimulate mucosal immunisation. Microbes Infect. 3 (2001), 867–876.
93. [93] Carr, K.E., Hazzard, R.A., Reid, S., Hodges, G.M., The effect of size on uptake of orally administered latex microparticles in the small intestine and transport to mesenteric lymph nodes. Pharm. Res. 13 (1996), 1205–1209.
94. [94] Gutierro, I., Hernandez, R.M., Igartua, M., Gascon, A.R., Pedraz, J.L., Influence of dose and immunization route on the serum Ig G antibody response to BSA loaded PLGA microspheres. Vaccine 20 (2002), 2181–2190.
95. [95] Kim, S.Y., Doh, H.J., Jang, M.H., Ha, Y.J., Chung, S.I., Park, H.J., Oral immunization with Helicobacter pylori-loaded poly(D,L-lactide-co-glycolide) nanoparticles. Helicobacter 4 (1999), 33–39.
96. [96] Jung, T., Kamm, W., Breitenbach, A., Hungerer, K.D., Hundt, E., Kissel, T., Tetanus toxoid loaded nanoparticles from sulfobutylated poly(vinyl alcohol)-graft-poly(lactide-co-glycolide): evaluation of antibody response after oral and nasal application in mice. Pharm. Res. 18 (2001), 352–360.
97. [97] Adomako, M., St-Hilaire, S., Zheng, Y., Eley, J., Marcum, R.D., Sealey, W., Donahower, B.C., Lapatra, S., Sheridan, P.P., Oral DNA vaccination of rainbow trout, Oncorhynchus mykiss (Walbaum), against infectious haematopoietic necrosis virus using PLGA [Poly(D,L-lactic-co-glycolic acid)] nanoparticles. J. Fish Dis. 35 (2012), 203–214.
98. [98] Smyth, S.H., Feldhaus, S., Schumacher, U., Carr, K.E., Uptake of inert microparticles in normal and immune deficient mice. Int. J. Pharm. 346 (2008), 109–118.
99. [99] Carr, R.M., Lolachi, C.M., Albaran, R.G., Ridley, D.M., Montgomery, P.C., O'sullivan, N.L., Nasal-associated lymphoid tissue is an inductive site for rat tear IgA antibody responses. Immunol. Investig. 25 (1996), 387–396.
100. [100] Lemoine, D., Wauters, F., Bouchend'Homme, S., Préat, V., Preparation and characterization of alginate microspheres containing a model antigen. Int. J. Pharm. 176 (1998), 9–19.
101. [101] Lemoine, D., Deschuyteneer, M., Hogge, F., Préat, V., Intranasal immunization against influenza virus using polymeric particles. J. Biomater. Sci. Polym. Ed. 10 (1999), 805–825.
102. [102] Köping-Höggård, M., Sánchez, A., Alonso, M.J., Nanoparticles as carriers for nasal vaccine delivery. 2005.
103. [103] Vila, A., Sanchez, A., Evora, C., Soriano, I., McCallion, O., Alonso, M., PLA–PEG particles as nasal protein carriers: the influence of the particle size. Int. J. Pharm. 292 (2005), 43–52.
104. [104] Mansoor, F., Earley, B., Cassidy, J.P., Markey, B., Doherty, S., Welsh, M.D., Comparing the immune response to a novel intranasal nanoparticle PLGA vaccine and a commercial BPI3V vaccine in dairy calves. BMC Vet. Res., 11, 2015, 220.
105. [105] Wang, G., Pan, L., Zhang, Y., Wang, Y., Zhang, Z., Lü, J., Zhou, P., Fang, Y., Jiang, S., Intranasal delivery of cationic PLGA nano/microparticles-loaded FMDV DNA vaccine encoding IL-6 elicited protective immunity against FMDV challenge. PLoS One, 6, 2011, e27605.
106. [106] Eyles, J.E., Sharp, G.J., Williamson, E.D., Spiers, I.D., Alpar, H.O., Intra nasal administration of poly-lactic acid microsphere co-encapsulated Yersinia pestis subunits confers protection from pneumonic plague in the mouse. Vaccine 16 (1998), 698–707.
107. [107] Vila, A., Sanchez, A., Evora, C., Soriano, I., Vila Jato, J., Alonso, M., PEG–PLA nanoparticles as carriers for nasal vaccine delivery. J. Aerosol Med. 17 (2004), 174–185.
108. [108] Ensign, L.M., Tang, B.C., Wang, Y.Y., Tse, T.A., Hoen, T., Cone, R., Hanes, J., Mucus-penetrating nanoparticles for vaginal drug delivery protect against herpes simplex virus. Sci. Transl. Med., 4, 2012, 138ra179.
109. [109] Lai, S.K., Wang, Y.Y., Hanes, J., Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv. Drug Deliv. Rev. 61 (2009), 158–171.
110. [110] Renukaradhya, G.J., Narasimhan, B., Mallapragada, S.K., Respiratory nanoparticle-based vaccines and challenges associated with animal models and translation. J. Control. Release 219 (2015), 622–631.
111. [111] Ulery, B.D., Kumar, D., Ramer-Tait, A.E., Metzger, D.W., Wannemuehler, M.J., Narasimhan, B., Design of a protective single-dose intranasal nanoparticle-based vaccine platform for respiratory infectious diseases. PLoS One, 6, 2011, e17642.
112. [112] Kean, T., Thanou, M., Biodegradation, biodistribution and toxicity of chitosan. Adv. Drug Deliv. Rev. 62 (2010), 3–11.
113. [113] Chadwick, S., Kriegel, C., Amiji, M., Nanotechnology solutions for mucosal immunization. Adv. Drug Deliv. Rev. 62 (2010), 394–407.
114. [114] Kobayashi, T., Fukushima, K., Sannan, T., Saito, N., Takiguchi, Y., Sato, Y., Hasegawa, H., Ishikawa, K., Evaluation of the effectiveness and safety of chitosan derivatives as adjuvants for intranasal vaccines. Viral Immunol. 26 (2013), 133–142.
115. [115] Vicente, S., Peleteiro, M., Diaz-Freitas, B., Sanchez, A., Gonzalez-Fernandez, A., Co-delivery of viral proteins and a TLR7 agonist from polysaccharide nanocapsules: a needle-free vaccination strategy. J. Control. Release 172 (2013), 773–781.
116. [116] van der Lubben, I.M., Kersten, G., Fretz, M.M., Beuvery, C., Coos Verhoef, J., Junginger, H.E., Chitosan microparticles for mucosal vaccination against diphtheria: oral and nasal efficacy studies in mice. Vaccine 21 (2003), 1400–1408.
117. [117] Augst, A.D., Kong, H.J., Mooney, D.J., Alginate hydrogels as biomaterials. Macromol. Biosci. 6 (2006), 623–633.
118. [118] De, S., Robinson, D., Polymer relationships during preparation of chitosan–alginate and poly-L-lysine–alginate nanospheres. J. Control. Release 89 (2003), 101–112.
119. [119] Rebelatto, M.C., Guimond, P., Bowersock, T.L., HogenEsch, H., Induction of systemic and mucosal immune response in cattle by intranasal administration of pig serum albumin in alginate microparticles. Vet. Immunol. Immunopathol. 83 (2001), 93–105.
120. [120] Malik, B., Microfold-cell targeted surface engineered polymeric nanoparticles for oral immunization. J. Drug Target. 20 (2012), 76–84.
121. [121] Tafaghodi, M., Rastegar, S., Preparation and in vivo study of dry powder microspheres for nasal immunization. J. Drug Target. 18 (2010), 235–242.
122. [122] Wang, S., Liu, H., Zhang, X., Qian, F., Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies. Protein Cell 6 (2015), 480–503.
123. [123] McDermott, M.R., Heritage, P.L., Bartzoka, V., Brook, M.A., Polymer-grafted starch microparticles for oral and nasal immunization. Immunol. Cell Biol. 76 (1998), 256–262.
124. [124] Rydell, N., Sjoholm, I., Oral vaccination against diphtheria using polyacryl starch microparticles as adjuvant. Vaccine 22 (2004), 1265–1274.
125. [125] Rydell, N., Sjoholm, I., Mucosal vaccination against diphtheria using starch microparticles as adjuvant for cross-reacting material (CRM197) of diphtheria toxin. Vaccine 23 (2005), 2775–2783.
126. [126] Wikingsson, L., Sjoholm, I., Polyacryl starch microparticles as adjuvant in oral immunisation, inducing mucosal and systemic immune responses in mice. Vaccine 20 (2002), 3355–3363.
127. [127] Illum, L., Fisher, A.N., Jabbal-Gill, I., Davis, S.S., Bioadhesive starch microspheres and absorption enhancing agents act synergistically to enhance the nasal absorption of polypeptides. Int. J. Pharm. 222 (2001), 109–119.
128. [128] Lee, T.Y., Kim, Y.H., Yoon, S.W., Choi, J.C., Yang, J.M., Kim, C.J., Schiller, J.T., Sung, M.H., Poo, H., Oral administration of poly-gamma-glutamate induces TLR4- and dendritic cell-dependent antitumor effect. Cancer Immunol. Immunother. 58 (2009), 1781–1794.
129. [129] Lin, Y.H., Chung, C.K., Chen, C.T., Liang, H.F., Chen, S.C., Sung, H.W., Preparation of nanoparticles composed of chitosan/poly-gamma-glutamic acid and evaluation of their permeability through Caco-2 cells. Biomacromolecules 6 (2005), 1104–1112.
130. [130] Moon, H.J., Lee, J.S., Talactac, M.R., Chowdhury, M.Y., Kim, J.H., Park, M.E., Choi, Y.K., Sung, M.H., Kim, C.J., Mucosal immunization with recombinant influenza hemagglutinin protein and poly gamma-glutamate/chitosan nanoparticles induces protection against highly pathogenic influenza A virus. Vet. Microbiol. 160 (2012), 277–289.
131. [131] Noh, H.J., Chowdhury, M.Y., Cho, S., Kim, J.H., Park, H.S., Kim, C.J., Poo, H., Sung, M.H., Lee, J.S., Lim, Y.T., Programming of influenza vaccine broadness and persistence by mucoadhesive polymer-based adjuvant systems. J. Immunol. 195 (2015), 2472–2482.
132. [132] Sahdev, P., Ochyl, L.J., Moon, J.J., Biomaterials for nanoparticle vaccine delivery systems. Pharm. Res. 31 (2014), 2563–2582.
133. [133] Singh, M., Briones, M., O'Hagan, D.T., A novel bioadhesive intranasal delivery system for inactivated influenza vaccines. J. Control. Release 70 (2001), 267–276.
134. [134] Saupe, A., McBurney, W., Rades, T., Hook, S., Immunostimulatory colloidal delivery systems for cancer vaccines. 2006.
135. [135] Wang, T., Jiang, H., Zhao, Q., Wang, S., Zou, M., Cheng, G., Enhanced mucosal and systemic immune responses obtained by porous silica nanoparticles used as an oral vaccine adjuvant: effect of silica architecture on immunological properties. Int. J. Pharm. 436 (2012), 351–358.
136. [136] Tao, W., Ziemer, K.S., Gill, H.S., Gold nanoparticle-M2e conjugate coformulated with CpG induces protective immunity against influenza A virus. Nanomedicine (London) 9 (2014), 237–251.
137. [137] Tao, W., Gill, H.S., M2e-immobilized gold nanoparticles as influenza A vaccine: role of soluble M2e and longevity of protection. Vaccine 33 (2015), 2307–2315.
138. [138] Wang, N., Wang, T., Zhang, M., Chen, R., Niu, R., Deng, Y., Mannose derivative and lipid A dually decorated cationic liposomes as an effective cold chain free oral mucosal vaccine adjuvant-delivery system. Eur. J. Pharm. Biopharm. 88 (2014), 194–206.
139. [139] Kang, S.-M., Yoo, D.-G., Lipatov, A.S., Song, J.-M., Davis, C.T., Quan, F.-S., Chen, L.-M., Donis, R.O., Compans, R.W., Induction of long-term protective immune responses by influenza H5N1 virus-like particles. PLoS One, 4, 2009, e4667.
140. [140] Atwe, S.U., Ma, Y., Gill, H.S., Pollen grains for oral vaccination. J. Control. Release 194 (2014), 45–52.
141. [141] Baca-Estrada, M.E., Foldvari, M., Babiuk, S.L., Babiuk, L.A., Vaccine delivery: lipid-based delivery systems. J. Biotechnol. 83 (2000), 91–104.
142. [142] Filipovic-Grcic, J., Skalko-Basnet, N., Jalsenjak, I., Mucoadhesive chitosan-coated liposomes: characteristics and stability. J. Microencapsul. 18 (2001), 3–12.
143. [143] Kaneda, Y., Development of a novel fusogenic viral liposome system (HVJ-liposomes) and its applications to the treatment of acquired diseases. Mol. Membr. Biol. 16 (1999), 119–122.
144. [144] Sakaue, G., Hiroi, T., Nakagawa, Y., Someya, K., Iwatani, K., Sawa, Y., Takahashi, H., Honda, M., Kunisawa, J., Kiyono, H., HIV mucosal vaccine: nasal immunization with gp160-encapsulated hemagglutinating virus of Japan-liposome induces antigen-specific CTLs and neutralizing antibody responses. J. Immunol. 170 (2003), 495–502.
145. [145] Minato, S., Iwanaga, K., Kakemi, M., Yamashita, S., Oku, N., Application of polyethyleneglycol (PEG)-modified liposomes for oral vaccine: effect of lipid dose on systemic and mucosal immunity. J. Control. Release 89 (2003), 189–197.
146. [146] Oberoi, H.S., Yorgensen, Y.M., Morasse, A., Evans, J.T., Burkhart, D.J., PEG modified liposomes containing CRX-601 adjuvant in combination with methylglycol chitosan enhance the murine sublingual immune response to influenza vaccination. J. Control. Release 223 (2016), 64–74.
147. [147] Perrie, Y., Crofts, F., Devitt, A., Griffiths, H.R., Kastner, E., Nadella, V., Designing liposomal adjuvants for the next generation of vaccines. Adv. Drug Deliv. Rev., 2015.
148. [148] Schwendener, R.A., Liposomes as vaccine delivery systems: a review of the recent advances. Ther. Adv. Vaccin. 2 (2014), 159–182.
149. [149] Zeltins, A., Construction and characterization of virus-like particles: a review. Mol. Biotechnol. 53 (2013), 92–107.
150. [150] Takamura, S., Niikura, M., Li, T.C., Takeda, N., Kusagawa, S., Takebe, Y., Miyamura, T., Yasutomi, Y., DNA vaccine-encapsulated virus-like particles derived from an orally transmissible virus stimulate mucosal and systemic immune responses by oral administration. Gene Ther. 11 (2004), 628–635.
151. [151] Mann, J.F., Scales, H.E., Shakir, E., Alexander, J., Carter, K.C., Mullen, A.B., Ferro, V.A., Oral delivery of tetanus toxoid using vesicles containing bile salts (bilosomes) induces significant systemic and mucosal immunity. Methods 38 (2006), 90–95.
152. [152] Kim, M.-C., Song, J.-M., Eunju, O., Kwon, Y.-M., Lee, Y.-J., Compans, R.W., Kang, S.-M., Virus-like particles containing multiple M2 extracellular domains confer improved cross-protection against various subtypes of influenza virus. Mol. Ther. 21 (2013), 485–492.
153. [153] Schwartzman, L.M., Cathcart, A.L., Pujanauski, L.M., Qi, L., Kash, J.C., Taubenberger, J.K., An intranasal virus-like particle vaccine broadly protects mice from multiple subtypes of influenza A virus. mBio, 6, 2015 (e01044–01015).
154. [154] Neirynck, S., Deroo, T., Saelens, X., Vanlandschoot, P., Jou, W.M., Fiers, W., A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat. Med. 5 (1999), 1157–1163.
155. [155] De Filette, M., Fiers, W., Martens, W., Birkett, A., Ramne, A., Löwenadler, B., Lycke, N., Jou, W.M., Saelens, X., Improved design and intranasal delivery of an M2e-based human influenza A vaccine. Vaccine 24 (2006), 6597–6601.
156. [156] De Filette, M., Jou, W.M., Birkett, A., Lyons, K., Schultz, B., Tonkyro, A., Resch, S., Fiers, W., Universal influenza A vaccine: optimization of M2-based constructs. Virology 337 (2005), 149–161.
157. [157] Bessa, J., Schmitz, N., Hinton, H.J., Schwarz, K., Jegerlehner, A., Bachmann, M.F., Efficient induction of mucosal and systemic immune responses by virus-like particles administered intranasally: implications for vaccine design. Eur. J. Immunol. 38 (2008), 114–126.
158. [158] Guerrero, R.A., Ball, J.M., Krater, S.S., Pacheco, S.E., Clements, J.D., Estes, M.K., Recombinant Norwalk virus-like particles administered intranasally to mice induce systemic and mucosal (fecal and vaginal) immune responses. J. Virol. 75 (2001), 9713–9722.
159. [159] Pedersen, G.K., Ebensen, T., Gjeraker, I.H., Svindland, S., Bredholt, G., Guzman, C.A., Cox, R.J., Evaluation of the sublingual route for administration of influenza H5N1 virosomes in combination with the bacterial second messenger c-di-GMP. PLoS One, 6, 2011, e26973.
160. [160] Vacher, G., Kaeser, M.D., Moser, C., Gurny, R., Borchard, G., Recent advances in Mucosal immunization using virus-like particles. Mol. Pharm. 10 (2013), 1596–1609.
161. [161] Shivanna, K.R., Pollen Biology and Biotechnology Science Publishers. 2003, Enfield, NH, USA.
162. [162] Roulston, T.H., Cane, J.H., Pollen nutritional content and digestibility for animals. Plant Syst. Evol. 222 (2000), 187–209.
163. [163] Barrier, S., Physical and Chemical Properties of Sporopollenin Exine Particles, in. 2008, The University of Hull, Hull.
164. [164] Jorde, W., Linskens, H.F., Zur persorption von pollen und spoken durch die intake darmschleimhaut. Acta Allergol. 29 (1974), 165–175.
165. [165] Kwon, K.-C., Verma, D., Singh, N.D., Herzog, R., Daniell, H., Oral delivery of human biopharmaceuticals, autoantigens and vaccine antigens bioencapsulated in plant cells. Adv. Drug Deliv. Rev. 65 (2013), 782–799.
166. [166] Tacket, C.O., Plant-based oral vaccines: results of human trials. Curr. Top. Microbiol. Immunol. 332 (2009), 103–117.
167. [167] Nochi, T., Takagi, H., Yuki, Y., Yang, L., Masumura, T., Mejima, M., Nakanishi, U., Matsumura, A., Uozumi, A., Hiroi, T., Morita, S., Tanaka, K., Takaiwa, F., Kiyono, H., Rice-based mucosal vaccine as a global strategy for cold-chain- and needle-free vaccination. Proc. Natl. Acad. Sci. U. S. A. 104 (2007), 10986–10991.
168. [168] Pniewski, T., The twenty-year story of a plant-based vaccine against hepatitis B: stagnation or promising prospects?. Int. J. Mol. Sci. 14 (2013), 1978–1998.
169. [169] Specht, E.A., Mayfield, S.P., Algae-based oral recombinant vaccines. Front. Microbiol., 5, 2014, 60.
170. [170] Dreesen, I.A.J., Hamri, G.C.-E., Fussenegger, M., Heat-stable oral alga-based vaccine protects mice from Staphylococcus aureus infection. J. Biotechnol. 145 (2010), 273–280.
171. [171] Gill, H.S., Prausnitz, M.R., Coated microneedles for transdermal delivery. J. Control. Release 117 (2007), 227–237.
172. [172] Gill, H.S., Soderholm, J., Prausnitz, M.R., Sallberg, M., Cutaneous vaccination using microneedles coated with hepatitis C DNA vaccine. Gene Ther. 17 (2010), 811–814.
173. [173] Shakya, A.K., Gill, H.S., A comparative study of microneedle-based cutaneous immunization with other conventional routes to assess feasibility of microneedles for allergy immunotherapy. Vaccine 33 (2015), 4060–4064.
174. [174] Pearson, F.E., McNeilly, C.L., Crichton, M.L., Primiero, C.A., Yukiko, S.R., Fernando, G.J., Chen, X., Gilbert, S.C., Hill, A.V., Kendall, M.A., Dry-coated live viral vector vaccines delivered by nanopatch microprojections retain long-term thermostability and induce transgene-specific T cell responses in mice. PLoS One, 8, 2013, e67888.
175. [175] Fernando, G.J., Chen, X., Primiero, C.A., Yukiko, S.R., Fairmaid, E.J., Corbett, H.J., Frazer, I.H., Brown, L.E., Kendall, M.A., Nanopatch targeted delivery of both antigen and adjuvant to skin synergistically drives enhanced antibody responses. J. Control. Release 159 (2012), 215–221.
176. [176] Gill, H.S., Denson, D.D., Burris, B.A., Prausnitz, M.R., Effect of microneedle design on pain in human volunteers. Clin. J. Pain 24 (2008), 585–594.
177. [177] Prausnitz, M.R., Mikszta, J.A., Cormier, M., Andrianov, A.K., Microneedle-based Vaccines. Compans, R.W., Orenstein, W.A., (eds.) Vaccines for Pandemic Influenza, 2009, Springer, Berlin Heidelberg, 369–393.
178. [178] Pattani, A., McKay, P.F., Garland, M.J., Curran, R.M., Migalska, K., Cassidy, C.M., Malcolm, R.K., Shattock, R.J., McCarthy, H.O., Donnelly, R.F., Microneedle mediated intradermal delivery of adjuvanted recombinant HIV-1 CN54gp140 effectively primes mucosal boost inoculations. J. Control. Release 162 (2012), 529–537.
179. [179] Weldon, W.C., Martin, M.P., Zarnitsyn, V., Wang, B., Koutsonanos, D., Skountzou, I., Prausnitz, M.R., Compans, R.W., Microneedle vaccination with stabilized recombinant influenza virus hemagglutinin induces improved protective immunity. Clin. Vaccine Immunol. 18 (2011), 647–654.
180. [180] Wang, B.-Z., Gill, H.S., He, C., Ou, C., Wang, L., Wang, Y.-C., Feng, H., Zhang, H., Prausnitz, M.R., Compans, R.W., Microneedle delivery of an M2e-TLR5 ligand fusion protein to skin confers broadly cross-protective influenza immunity. J. Control. Release 178 (2014), 1–7.
181. [181] Ma, Y., Tao, W., Krebs, S.J., Sutton, W.F., Haigwood, N.L., Gill, H.S., Vaccine delivery to the oral cavity using coated microneedles induces systemic and mucosal immunity. Pharm. Res. 31 (2014), 2393–2403.
182. [182] Zhen, Y., Wang, N., Gao, Z., Ma, X., Wei, B., Deng, Y., Wang, T., Multifunctional liposomes constituting microneedles induced robust systemic and mucosal immunoresponses against the loaded antigens via oral mucosal vaccination. Vaccine 33 (2015), 4330–4340.
183. [183] Park, H.J., Ferko, B., Byun, Y.H., Song, J.H., Han, G.Y., Roethl, E., Egorov, A., Muster, T., Seong, B., Kweon, M.N., Song, M., Czerkinsky, C., Nguyen, H.H., Sublingual immunization with a live attenuated influenza a virus lacking the nonstructural protein 1 induces broad protective immunity in mice. PLoS One, 7, 2012, e39921.
184. [184] Appledorn, D.M., Aldhamen, Y.A., Godbehere, S., Seregin, S.S., Amalfitano, A., Sublingual administration of an adenovirus serotype 5 (Ad5)-based vaccine confirms Toll-like receptor agonist activity in the oral cavity and elicits improved mucosal and systemic cell-mediated responses against HIV antigens despite preexisting Ad5 immunity. Clin. Vaccine Immunol. 18 (2011), 150–160.
185. [185] Amuguni, J.H., Lee, S., Kerstein, K.O., Brown, D.W., Belitsky, B.R., Herrmann, J.E., Keusch, G.T., Sonenshein, A.L., Tzipori, S., Sublingually administered Bacillus subtilis cells expressing tetanus toxin C fragment induce protective systemic and mucosal antibodies against tetanus toxin in mice. Vaccine 29 (2011), 4778–4784.
186. [186] Murugappan, S., Patil, H.P., Frijlink, H.W., Huckriede, A., Hinrichs, W.L., Simplifying influenza vaccination during pandemics: sublingual priming and intramuscular boosting of immune responses with heterologous whole inactivated influenza vaccine. AAPS J. 16 (2014), 342–349.
187. [187] Hervouet, C., Luci, C., Cuburu, N., Cremel, M., Bekri, S., Vimeux, L., Maranon, C., Czerkinsky, C., Hosmalin, A., Anjuere, F., Sublingual immunization with an HIV subunit vaccine induces antibodies and cytotoxic T cells in the mouse female genital tract. Vaccine 28 (2010), 5582–5590.
188. [188] Gallorini, S., Taccone, M., Bonci, A., Nardelli, F., Casini, D., Bonificio, A., Kommareddy, S., Bertholet, S., O'Hagan, D.T., Baudner, B.C., Sublingual immunization with a subunit influenza vaccine elicits comparable systemic immune response as intramuscular immunization, but also induces local IgA and TH17 responses. Vaccine 32 (2014), 2382–2388.
189. [189] Huang, C.F., Wu, T.C., Wu, C.C., Lee, C.C., Lo, W.T., Hwang, K.S., Hsu, M.L., Peng, H.J., Sublingual vaccination with sonicated Salmonella proteins and mucosal adjuvant induces mucosal and systemic immunity and protects mice from lethal enteritis. APMIS 119 (2011), 468–478.
190. [190] Buffa, V., Klein, K., Fischetti, L., Shattock, R.J., Evaluation of TLR agonists as potential mucosal adjuvants for HIV gp140 and tetanus toxoid in mice. PLoS One, 7, 2012, e50529.
191. [191] Cho, H.J., Kim, J.Y., Lee, Y., Kim, J.M., Kim, Y.B., Chun, T., Oh, Y.K., Enhanced humoral and cellular immune responses after sublingual immunization against human papillomavirus 16L1 protein with adjuvants. Vaccine 28 (2010), 2598–2606.
192. [192] Canonica, G.W., Cox, L., Pawankar, R., Baena-Cagnani, C.E., Blaiss, M., Bonini, S., Bousquet, J., Calderon, M., Compalati, E., Durham, S.R., van Wijk, R.G., Larenas-Linnemann, D., Nelson, H., Passalacqua, G., Pfaar, O., Rosario, N., Ryan, D., Rosenwasser, L., Schmid-Grendelmeier, P., Senna, G., Valovirta, E., Van Bever, H., Vichyanond, P., Wahn, U., Yusuf, O., Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organ. J., 7, 2014, 6.
193. [193] Grier, T.J., LeFevre, D.M., Duncan, E.A., Esch, R.E., Stability of standardized grass, dust mite, cat, and short ragweed allergens after mixing with mold or cockroach extracts. Ann. Allergy Asthma Immunol. 99 (2007), 151–160.
194. [194] White, J.A., Blum, J.S., Hosken, N.A., Marshak, J.O., Duncan, L., Zhu, C., Norton, E.B., Clements, J.D., Koelle, D.M., Chen, D., Weldon, W.C., Oberste, M.S., Lal, M., Serum and mucosal antibody responses to inactivated polio vaccine after sublingual immunization using a thermoresponsive gel delivery system. Hum. Vaccin. Immunother. 10 (2014), 3611–3621.
195. [195] Narang, N., Sharma, J., Sublingual mucosa as a route for systemic drug delivery. Int. J. Pharm. Pharm. Sci. 3:Suppl. 2 (2011), 18–22 (2011, 1822, 3).
196. [196] Borde, A., Ekman, A., Holmgren, J., Larsson, A., Effect of protein release rates from tablet formulations on the immune response after sublingual immunization. Eur. J. Pharm. Sci. 47 (2012), 695–700.
197. [197] Glenn, G.M., Scharton-Kersten, T., Vassell, R., Matyas, G.R., Alving, C.R., Transcutaneous immunization with bacterial ADP-ribosylating exotoxins as antigens and adjuvants. Infect. Immun. 67 (1999), 1100–1106.
198. [198] Gockel, C.M., Bao, S., Beagley, K.W., Transcutaneous immunization induces mucosal and systemic immunity: a potent method for targeting immunity to the female reproductive tract. Mol. Immunol. 37 (2000), 537–544.
199. [199] Loudon, P.T., Yager, E.J., Lynch, D.T., Narendran, A., Stagnar, C., Franchini, A.M., Fuller, J.T., White, P.A., Nyuandi, J., Wiley, C.A., Murphey-Corb, M., Fuller, D.H., GM-CSF increases mucosal and systemic immunogenicity of an H1N1 influenza DNA vaccine administered into the epidermis of non-human primates. PLoS One, 5, 2010, e11021.
200. [200] Fuller, D.H., Rajakumar, P.A., Wilson, L.A., Trichel, A.M., Fuller, J.T., Shipley, T., Wu, M.S., Weis, K., Rinaldo, C.R., Haynes, J.R., Murphey-Corb, M., Induction of mucosal protection against primary, heterologous simian immunodeficiency virus by a DNA vaccine. J. Virol. 76 (2002), 3309–3317.
201. [201] Drape, R.J., Macklin, M.D., Barr, L.J., Jones, S., Haynes, J.R., Dean, H.J., Epidermal DNA vaccine for influenza is immunogenic in humans. Vaccine 24 (2006), 4475–4481.
202. [202] Jones, S., Evans, K., McElwaine-Johnn, H., Sharpe, M., Oxford, J., Lambkin-Williams, R., Mant, T., Nolan, A., Zambon, M., Ellis, J., Beadle, J., Loudon, P.T., DNA vaccination protects against an influenza challenge in a double-blind randomised placebo-controlled phase 1b clinical trial. Vaccine 27 (2009), 2506–2512.
203. [203] Engelke, L., Winter, G., Hook, S., Engert, J., Recent insights into cutaneous immunization: how to vaccinate via the skin. Vaccine 33 (2015), 4663–4674.
204. [204] Mitragotri, S., Immunization without needles. Nat. Rev. Immunol. 5 (2005), 905–916.
205. [205] Gill, H.S., Kang, S.-M., Quan, F.-S., Compans, R.W., Cutaneous immunization: an evolving paradigm in influenza vaccines. Expert Opin. Drug Deliv. 11 (2014), 615–627.
206. [206] McElrath, M.J., Selection of potent immunological adjuvants for vaccine construction. Seminars in cancer biology, 1995, Elsevier, 375–385.
207. [207] Stevceva, L., Ferrari, M.G., Mucosal adjuvants. Curr. Pharm. Des. 11 (2005), 801–811.
208. [208] Wilson-Welder, J.H., Torres, M.P., Kipper, M.J., Mallapragada, S.K., Wannemuehler, M.J., Narasimhan, B., Vaccine adjuvants: current challenges and future approaches. J. Pharm. Sci. 98 (2009), 1278–1316.
209. [209] Jones, K.S., Biomaterials as vaccine adjuvants. Biotechnol. Prog. 24 (2008), 807–814.
210. [210] Freytag, L.C., Clements, J.D., Mucosal adjuvants. Vaccine 23 (2005), 1804–1813.
211. [211] Pizza, M., Giuliani, M.M., Fontana, M.R., Monaci, E., Douce, G., Dougan, G., Mills, K.H., Rappuoli, R., Del Giudice, G., Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants. Vaccine 19 (2001), 2534–2541.
212. [212] Sanchez, J., Wallerstrom, G., Fredriksson, M., Angstrom, J., Holmgren, J., Detoxification of cholera toxin without removal of its immunoadjuvanticity by the addition of (STa-related) peptides to the catalytic subunit. A potential new strategy to generate immunostimulants for vaccination. J. Biol. Chem. 277 (2002), 33369–33377.
213. [213] Takeuchi, O., Akira, S., Pattern recognition receptors and inflammation. Cell 140 (2010), 805–820.
214. [214] Chabot, S., Wagner, J.S., Farrant, S., Neutra, M.R., TLRs regulate the gatekeeping functions of the intestinal follicle-associated epithelium. J. Immunol. 176 (2006), 4275–4283.
215. [215] Cario, E., Podolsky, D.K., Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect. Immun. 68 (2000), 7010–7017.
216. [216] Moore, A., McCarthy, L., Mills, K.H., The adjuvant combination monophosphoryl lipid A and QS21 switches T cell responses induced with a soluble recombinant HIV protein from Th2 to Th1. Vaccine 17 (1999), 2517–2527.
217. [217] Baldridge, J.R., McGowan, P., Evans, J.T., Cluff, C., Mossman, S., Johnson, D., Persing, D., Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents. Expert. Opin. Biol. Ther. 4 (2004), 1129–1138.
218. [218] Ulrich, J.T., Myers, K.R., Monophosphoryl lipid A as an adjuvant. Past experiences and new directions. Pharm. Biotechnol. 6 (1995), 495–524.
219. [219] Krieg, A.M., Yi, A.-K., Matson, S., Waldschmidt, T.J., Bishop, G.A., Teasdale, R., Koretzky, G.A., Klinman, D.M., CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374 (1995), 546–549.
220. [220] Klinman, D.M., Currie, D., Gursel, I., Verthelyi, D., Use of CpG oligodeoxynucleotides as immune adjuvants. Immunol. Rev. 199 (2004), 201–216.
221. [221] Yi, A.-K., Hornbeck, P., Lafrenz, D.E., Krieg, A.M., CpG DNA rescue of murine B lymphoma cells from anti-IgM-induced growth arrest and programmed cell death is associated with increased expression of c-myc and bcl-xL. J. Immunol. 157 (1996), 4918–4925.
222. [222] Lipford, G.B., Bauer, M., Blank, C., Reiter, R., Wagner, H., Heeg, K., CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: A new class of vaccine adjuvants. Eur. J. Immunol. 27 (1997), 2340–2344.
223. [223] Chu, R.S., Targoni, O.S., Krieg, A.M., Lehmann, P.V., Harding, C.V., CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J. Exp. Med. 186 (1997), 1623–1631.
224. [224] Singh, S., Yang, G., Byrareddy, S.N., Barry, M.A., Sastry, K.J., Natural killer T cell and TLR9 agonists as mucosal adjuvants for sublingual vaccination with clade C HIV-1 envelope protein. Vaccine 32 (2014), 6934–6940.
225. [225] Alexopoulou, L., Holt, A.C., Medzhitov, R., Flavell, R.A., Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 413 (2001), 732–738.
226. [226] Stowell, N.C., Seideman, J., Raymond, H.A., Smalley, K.A., Lamb, R.J., Egenolf, D.D., Bugelski, P.J., Murray, L.A., Marsters, P.A., Bunting, R.A., Flavell, R.A., Alexopoulou, L., San Mateo, L.R., Griswold, D.E., Sarisky, R.T., Mbow, M.L., Das, A.M., Long-term activation of TLR3 by poly(I:C) induces inflammation and impairs lung function in mice. Respir. Res., 10, 2009, 43.
227. [227] Schulz, O., Diebold, S.S., Chen, M., Naslund, T.I., Nolte, M.A., Alexopoulou, L., Azuma, Y.T., Flavell, R.A., Liljestrom, P., Sousa, C. Reis e, Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature 433 (2005), 887–892.
228. [228] Schroder, M., Bowie, A.G., TLR3 in antiviral immunity: key player or bystander?. Trends Immunol. 26 (2005), 462–468.
229. [229] Sloat, B.R., Cui, Z., Nasal immunization with a dual antigen anthrax vaccine induced strong mucosal and systemic immune responses against toxins and bacilli. Vaccine 24 (2006), 6405–6413.
230. [230] Sloat, B.R., Shaker, D.S., Le, U.M., Cui, Z., Nasal immunization with the mixture of PA63, LF, and a PGA conjugate induced strong antibody responses against all three antigens. FEMS Immunol. Med. Microbiol. 52 (2008), 169–179.
231. [231] Akira, S., Innate immunity and adjuvants. Philos. Trans. R. Soc. Lond. Ser. B Biol. Sci. 366 (2011), 2748–2755.
232. [232] Honko, A.N., Mizel, S.B., Effects of flagellin on innate and adaptive immunity. Immunol. Res. 33 (2005), 83–101.
233. [233] Tsujimoto, H., Uchida, T., Efron, P.A., Scumpia, P.O., Verma, A., Matsumoto, T., Tschoeke, S.K., Ungaro, R.F., Ono, S., Seki, S., Flagellin enhances NK cell proliferation and activation directly and through dendritic cell-NK cell interactions. J. Leukoc. Biol. 78 (2005), 888–897.
234. [234] Honko, A.N., Sriranganathan, N., Lees, C.J., Mizel, S.B., Flagellin is an effective adjuvant for immunization against lethal respiratory challenge with Yersinia pestis. Infect. Immun. 74 (2006), 1113–1120.
235. [235] Wang, B.-Z., Xu, R., Quan, F.-S., Kang, S.-M., Wang, L., Compans, R.W., Intranasal immunization with influenza VLPs incorporating membrane-anchored flagellin induces strong heterosubtypic protection. 2010.
236. [236] Lee, S.E., Kim, S.Y., Jeong, B.C., Kim, Y.R., Bae, S.J., Ahn, O.S., Lee, J.-J., Song, H.-C., Kim, J.M., Choy, H.E., A bacterial flagellin, Vibrio vulnificus FlaB, has a strong mucosal adjuvant activity to induce protective immunity. Infect. Immun. 74 (2006), 694–702.
237. [237] Nacer, A., Carapau, D., Mitchell, R., Meltzer, A., Shaw, A., Frevert, U., Nardin, E.H., Imaging murine NALT following intranasal immunization with flagellin-modified circumsporozoite protein malaria vaccines. Mucosal Immunol. 7 (2014), 304–314.
238. [238] Ben-Yedidia, T., Tarrab-Hazdai, R., Schechtman, D., Arnon, R., Intranasal administration of synthetic recombinant peptide-based vaccine protects mice from infection by Schistosoma mansoni. Infect. Immun. 67 (1999), 4360–4366.
239. [239] Vassilieva, E.V., Wang, B.-Z., Vzorov, A.N., Wang, L., Wang, Y.-C., Bozja, J., Xu, R., Compans, R.W., Enhanced mucosal immune responses to HIV virus-like particles containing a membrane-anchored adjuvant. MBio, 2, 2011 (e00328–00310).
240. [240] Kayamuro, H., Yoshioka, Y., Abe, Y., Arita, S., Katayama, K., Nomura, T., Yoshikawa, T., Kubota-Koketsu, R., Ikuta, K., Okamoto, S., Mori, Y., Kunisawa, J., Kiyono, H., Itoh, N., Nagano, K., Kamada, H., Tsutsumi, Y., Tsunoda, S., Interleukin-1 family cytokines as mucosal vaccine adjuvants for induction of protective immunity against influenza virus. J. Virol. 84 (2010), 12703–12712.
241. [241] Rhee, J.H., Lee, S.E., Kim, S.Y., Mucosal vaccine adjuvants update. Clin. Exp. Vaccine Res. 1 (2012), 50–63.
242. [242] Carbonneil, C., Aouba, A., Burgard, M., Cardinaud, S., Rouzioux, C., Langlade-Demoyen, P., Weiss, L., Dendritic cells generated in the presence of granulocyte–macrophage colony-stimulating factor and IFN-alpha are potent inducers of HIV-specific CD8 T cells. AIDS 17 (2003), 1731–1740.
243. [243] Carbonneil, C., Saidi, H., Donkova-Petrini, V., Weiss, L., Dendritic cells generated in the presence of interferon-alpha stimulate allogeneic CD4 + T-cell proliferation: modulation by autocrine IL-10, enhanced T-cell apoptosis and T regulatory type 1 cells. Int. Immunol. 16 (2004), 1037–1052.
244. [244] Tighe, H., Corr, M., Roman, M., Raz, E., Gene vaccination: plasmid DNA is more than just a blueprint. Immunol. Today 19 (1998), 89–97.
245. [245] Coulter, A., Harris, R., Davis, R., Drane, D., Cox, J., Ryan, D., Sutton, P., Rockman, S., Pearse, M., Intranasal vaccination with ISCOMATRIX adjuvanted influenza vaccine. Vaccine 21 (2003), 946–949.
246. [246] Vujanic, A., Snibson, K.J., Wee, J.L., Edwards, S.J., Pearse, M.J., Scheerlinck, J.P., Sutton, P., Long-term antibody and immune memory response induced by pulmonary delivery of the influenza Iscomatrix vaccine. Clin. Vaccine Immunol. 19 (2012), 79–83.
247. [247] Lu, Y.J., Yadav, P., Clements, J.D., Forte, S., Srivastava, A., Thompson, C.M., Seid, R., Look, J., Alderson, M., Tate, A., Maisonneuve, J.F., Robertson, G., Anderson, P.W., Malley, R., Options for inactivation, adjuvant, and route of topical administration of a killed, unencapsulated pneumococcal whole-cell vaccine. Clin. Vaccine Immunol. 17 (2010), 1005–1012.
248. [248] Meng, S., Liu, Z., Xu, L., Li, L., Mei, S., Bao, L., Deng, W., Lei, R., Xie, L., Qin, C., Zhang, L., Intranasal immunization with recombinant HA and mast cell activator C48/80 elicits protective immunity against 2009 pandemic H1N1 influenza in mice. PLoS One, 6, 2011 e19863.
249. [249] Staats, H.F., Fielhauer, J.R., Thompson, A.L., Tripp, A.A., Sobel, A.E., Maddaloni, M., Abraham, S.N., Pascual, D.W., Mucosal targeting of a BoNT/A subunit vaccine adjuvanted with a mast cell activator enhances induction of BoNT/A neutralizing antibodies in rabbits. PLoS One, 6, 2011 e16532.
250. [250] Somavarapu, S., Pandit, S., Gradassi, G., Bandera, M., Ravichandran, E., Alpar, O.H., Effect of vitamin E TPGS on immune response to nasally delivered diphtheria toxoid loaded poly(caprolactone) microparticles. Int. J. Pharm. 298 (2005), 344–347.
251. [251] Agrawal, S., Gupta, S., Agrawal, A., Human dendritic cells activated via dectin-1 are efficient at priming Th17, cytotoxic CD8 T and B cell responses. PLoS One, 5, 2010 e13418.
252. [252] Gleeson, M., Cripps, A.W., Development of mucosal immunity in the first year of life and relationship to sudden infant death syndrome. FEMS Immunol. Med. Microbiol. 42 (2004), 21–33.
253. [253] Teitelbaum, J.E., Allan Walker, W., The development of mucosal immunity. Eur. J. Gastroenterol. Hepatol. 17 (2005), 1273–1278.
254. [254] Brandtzaeg, P., Potential of nasopharynx-associated lymphoid tissue for vaccine responses in the airways. Am. J. Respir. Crit. Care Med. 183 (2011), 1595–1604.
255. [255] Axelsson, I., Jakobsson, I., Lindberg, T., Polberger, S., Benediktsson, B., Räihä, N., Macromolecular absorption in preterm and term infants. Acta Paediatr. 78 (1989), 532–537.
256. [256] Insoft, R.M., Sanderson, I.R., Walker, W.A., Development of immune function in the intestine and its role in neonatal diseases. Pediatr. Clin. N. Am. 43 (1996), 551–571.
257. [257] Hale, C., Humphreys, I.R., Hussell, T., Bowe, F., Clare, S., Pickard, D., Preston, A., Del Giudice, G., Dougan, G., Mucosal immunisation of murine neonates using whole cell and acellular Pertussis vaccines. Vaccine 22 (2004), 3595–3602.
258. [258] Capozzo, A.V.E., Cuberos, L., Levine, M.M., Pasetti, M.F., Mucosally delivered Salmonella live vector vaccines elicit potent immune responses against a foreign antigen in neonatal mice born to naive and immune mothers. Infect. Immun. 72 (2004), 4637–4646.
259. [259] John, M., Bridges, E.A., Miller, A.O., Calderwood, S.B., Ryan, E.T., Comparison of mucosal and systemic humoral immune responses after transcutaneous and oral immunization strategies. Vaccine 20 (2002), 2720–2726.